ADAPTIVE PHAGE THERAPEUTICS, LLC

ADAPTIVE PHAGE THERAPEUTICS, LLC specializes in the research, development, and translational application of bacteriophage-based therapeutics for targeted antimicrobial interventions. Leveraging advanced molecular biology and virology techniques, the company focuses on engineering precision phage cocktails to combat multidrug-resistant bacterial infections, with expertise in phage isolation, host-range characterization, genomic sequencing, and formulation for clinical delivery. Their technical capabilities include high-throughput phage screening, bioinformatics-driven host-pathogen matching, and GMP-compatible production processes tailored for therapeutic use in immunocompromised or chronically infected populations. The firm’s key differentiator lies in its adaptive phage selection platforms, which enable rapid response to evolving bacterial resistance profiles, positioning them at the intersection of infectious disease innovation and precision medicine. Award history is not available to infer specific agency engagements or project types. Consequently, no patterns of collaboration with federal entities can be confirmed from the provided data. The primary NAICS code 541715 reflects research and development in the life sciences, specifically in biotechnology research services. In practice, this indicates the company operates as a specialized R&D entity focused on preclinical and early-stage therapeutic development rather than large-scale manufacturing or clinical trial management. Their market positioning is that of a niche biotech innovator advancing next-generation antimicrobial solutions within the federal biomedical research ecosystem. ADAPTIVE PHAGE THERAPEUTICS, LLC is structured as a small business (2L) with its operational base in Gaithersburg, Maryland, a recognized hub for federal biomedical research. The company holds no government certifications, and its market presence is defined by its scientific expertise rather than formal socio-economic status designations. It operates as a focused R&D provider within the federal biodefense and infectious disease research landscape.